Special Issue "Recent Advancements in Nanobiotechnology and Immunotherapy for the Treatment of Solid Tumors"
Deadline for manuscript submissions: closed (20 August 2023) | Viewed by 2932
Interests: nanoparticles; immunotherapy; tumor immunology; targeted therapy
Interests: drug delivery; nanotechnologies; polymer therapeutics; skin delivery; biomaterials for tissue engineering
Special Issues, Collections and Topics in MDPI journals
Onco-immunotherapies, such as immune checkpoint blockade inhibitors and adoptive cell therapies, are revolutionizing the field of cancer therapy due to their ability to induce strong anti-tumor immune responses. Many novel immune-based cancer therapies are rapidly moving from the bench to the clinic. However, despite being very effective in hematological and some solid tumors, unresponsiveness, development of therapy resistance, and serious adverse effects limit their capacity to impact the vast majority of solid tumors. The use of nanoparticle-based delivery systems (NPs) to improve conventional onco-immunotherapies is gaining traction due largely to the versatility of this approach; these systems can be loaded with a wide variety of molecular cargoes and finely tuned to release their contents into the tumor microenvironment. NPs can be engineered to deliver combinations of adjuvants and antigens, as in the case of nanovaccines. This Special Issue aims to collect manuscripts related to the development of novel nanotherapeutics to remodel the tumor microenvironment and enhance immunotherapies for the treatment of solid tumors.
We are inviting the submission of high-quality research papers and reviews exploring the synergistic combinations between nanotherapeutics and immunomodulatory molecules for the treatment of solid tumors. We expect to receive contributions from different areas of multidisciplinary research, including (but not restricted to): innovative immunomodulatory nanomaterial design, NP surface functionalization and characterization, the relationship between the physicochemical properties of NPs and their immunomodulation properties, and potential new therapeutic applications in solid tumor treatment. This Special Issue aims to make a significant collective contribution to this field of study and facilitate the development of new therapeutic approaches for cancer patients.
We look forward to receiving your contributions.
Dr. Francesco Mainini
Dr. Ovidio Catanzano
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- solid tumors
- adoptive cell therapy
- tumor microenvironment
- immune checkpoint